News Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 19:14:06 11/02/2026 GMT			5-day change	1st Jan Change
364.38 ^USD	-0.07%		-0.58%	+11.23%

02-10	Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating	MT
02-10	Daiwa Securities Adjusts Price Target on Amgen to $410 From $370, Maintains Outperform Rating	MT

All News

06:10am	USPTO Restores Strict RPI Filing Date Rule	AQ
02-10	Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating	MT
02-10	Daiwa Securities Adjusts Price Target on Amgen to $410 From $370, Maintains Outperform Rating	MT
02-09	Amgen : When Advocacy Meets Science in the Care of People Living with gMG	PU
02-06	Guggenheim Adjusts Price Target on Amgen to $347 From $305, Maintains Neutral Rating	MT
02-06	Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating	MT
02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
02-05	Deutsche Bank Adjusts Amgen Price Target to $295 From $285, Maintains Hold Rating	MT
02-04	Health Care Up After Eli Lilly Earnings -- Health Care Roundup	DJ
02-04	Sector Update: Health Care Stocks Rise Late Afternoon	MT
02-04	Amgen Seen Driving Long-Term Growth on R&D Pipeline, Oppenheimer Says	MT
02-04	Novo Nordisk exposed to a price war over obesity treatments
02-04	Novo Nordisk risks weight-loss price war as discount pressures deepen	RE
02-04	TD Cowen Adjusts Price Target on Amgen to $420 From $389, Maintains Buy Rating	MT
02-04	Leerink Partners Adjusts Price Target on Amgen to $355 From $305, Maintains Market Perform Rating	MT
02-04	Citigroup Adjusts Price Target on Amgen to $345 From $315, Maintains Neutral Rating	MT
02-04	Cantor Fitzgerald Adjusts Price Target on Amgen to $350 From $315, Maintains Neutral Rating	MT
02-04	Novo Nordisk risks weight-loss price war as discount pressures deepen	RE
02-04	Health Rounds: Cancer immunotherapies may be more effective given earlier in the day	RE
02-04	RBC Raises Price Target on Amgen to $360 From $335, Keeps Outperform Rating	MT
02-04	Morgan Stanley Raises Price Target on Amgen to $309 From $304, Keeps Equalweight Rating	MT
02-04	Goldman Sachs Adjusts Price Target on Amgen to $415 From $403, Maintains Buy Rating	MT
02-03	Amgen posts Q4 total revenue $9.87 bln vs IBES estimate $9.47 bln	RE
02-03	Amgen Inc., Q4 2025 Earnings Call, Feb 03, 2026
02-03	Amgen : Highlights from Amgen's 2025 Fourth Quarter and Full Year Earnings Report	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

All News

Filters